Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory CLL and require treatment in opinion of investigator.~* Eastern Cooperative Oncology Group (ECOG) \<= 1.~* Adequate bone marrow independent of growth factor support, renal and hepatic function per defined laboratory criteria.~Exclusion Criteria:~* History or is clinically suspicious for cancer-related Central Nervous System disease.~* Receipt of allogenic or autologous stem cell transplant.~* Recent history (within 1 year of first dose) of underlying, predisposing condition of bleeding or currently exhibits signs of bleeding.~* Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.~* Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within 1 year of first dose).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Navitoclax 14/21 Day Cycle: 10 mg (Type: EXPERIMENTAL): Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 110 mg (Type: EXPERIMENTAL): Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 200 mg (Type: EXPERIMENTAL): Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 14/21 Day Cycle: 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 125 mg (Type: EXPERIMENTAL): Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 200 mg (Type: EXPERIMENTAL): Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.
- Navitoclax 21/21 Day Cycle: 300 mg (Type: EXPERIMENTAL): Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.
- Phase 2: Navitoclax 100 mg (Type: EXPERIMENTAL): Navitoclax 100 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
- Phase 2: Navitoclax 250 mg (Type: EXPERIMENTAL): Navitoclax 250 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).